Oxford Science Enterprises backs the renowned Oxford Immunologists Prof. Omer Dushekt & Prof. Anton van der Merwe with MatchBio, an enabling technology company that provides solutions to the longstanding issue of low-sensitivity of CAR-T therapy; MatchBio seeks to reduce relapse, increase specificity and expand the target landscape for current CAR-based therapeutics.